NBP (dl-3-n-butylphthalide, Product name: En Bi Pu) is China`s first anti-cerebral ischemia new drug with full intellectual property, that was discovered and developed by Institute of Material and Medica, CAMS. NBP is clinically used for the treatment of mild to moderate acute ischemic stroke. Phase IV clinical trials of NBP have been accomplished under the leadership of Peking Union Medical College Hospital in 2005. A total of 2560 cases were collected from 94 hospitals in 11 regions of the country according to international ICH standards. It was the largest clinical trial in China at that time. The trial demonstrated that NBP was safe and effective in the treatment of ischemic stroke. Our studies confirmed that dl-NBP is a multi-targeted drug. It protected mitochondrial function, attenuated apoptosis and inhibited platelet aggregation. NBP has been widely used in patients with acute cerebral ischemia and has an annual sale of over 1 billion RMB, accounting for an important domestic market share of the first type of new drug in China.